CompletedPhase 2NCT04357730

Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Denver Health and Hospital Authority
Principal Investigator
Ernest E Moore, MD
Denver Health Medical Center (DHMC)
Intervention
Alteplase 50 MG [Activase](drug)
Enrollment
50 enrolled
Eligibility
18-75 years · All sexes
Timeline
20202021

Study locations (9)

Collaborators

Genentech, Inc. · University of Colorado, Denver · National Jewish Health · Beth Israel Deaconess Medical Center · Long Island Jewish Medical Center · Scripps Health · St. Mary's Medical Center · University of Miami · Ben Taub Hospital · The Methodist Hospital Research Institute

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04357730 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials